Targeted short-term fluconazole prophylaxis among very low birth weight and extremely low birth weight infants.
OBJECTIVE
To assess whether targeted short-term fluconazole prophylaxis reduces late-onset (>3 days of age) invasive fungal infection (IFI) among very low birth weight infants and extremely low birth weight (ELBW) infants and to assess mortality rates, toxicity, and costs associated with this intervention.


METHODS
An observational study of 2 subsequent epochs of inborn infants with birth weight of <1500 g or gestational age of <32 weeks, 1 before (control) and 1 after (fluconazole) initiation of routine targeted fluconazole prophylaxis in March 2003, was performed. Targeted fluconazole (3 mg/kg) prophylaxis was administered to infants for whom a decision was made to administer broad-spectrum antibiotics for >3 days.


RESULTS
IFI was observed for 13 (6.3%) of 206 infants in the control epoch and 2 (1.1%) of 178 in the fluconazole epoch, with a common odds ratio of 0.166. Logistic regression analysis taking into account all published factors (except for fungal colonization) showed that the fluconazole epoch was associated significantly with lower IFI rates. We observed no change in late (>3 days) mortality rates (11 of 206 infants in the control epoch vs 8 of 178 infants in the prophylaxis epoch). The mortality rate for ELBW infants with IFI was low (15%) in our study. Fluconazole was administered to 81% of ELBW infants, who received a median of 8 doses, and 41% of larger infants, who received a median of 5 doses. The intervention was cost-effective, and the effective number needed to treat to prevent 1 IFI was 10.


CONCLUSIONS
This study suggests that targeted short-course fluconazole prophylaxis in very low birth weight and ELBW infants may be efficacious and cost effective.
Uko
Smart
S
Division of Neonatology, Department of Pediatrics, Albert Einstein College of Medicine, Children's Hospital at Montefiore, Bronx, New York, USA.
Soghier
Lamia M
LM
Vega
Melissa
M
Marsh
Jeremy
J
Reinersman
Gerald T
GT
Herring
Lucille
L
Dave
Viral A
VA
Nafday
Suhas
S
Brion
Luc P
LP
D019072:Antibiotic Prophylaxis; D000935:Antifungal Agents / Q000008:administration & dosage* / Q000191:economics; D002177:Candidiasis / Q000401:mortality / Q000517:prevention & control; D015725:Fluconazole / Q000008:administration & dosage* / Q000191:economics; D017048:Health Care Costs; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D007235:Infant, Premature, Diseases / Q000191:economics / Q000401:mortality / Q000517:prevention & control*; D019102:Infant, Very Low Birth Weight; D009181:Mycoses / Q000191:economics / Q000401:mortality / Q000517:prevention & control*; D015996:Survival Rate
D000935:Antifungal Agents; D015725:Fluconazole